Citi Downgrades PTC Therapeutics (PTCT) to Neutral
Tweet
Share
E-mail
Get Alerts PTCT Hot Sheet
Price: $78.47 -0.47%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 15 | New: 12
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 15 | New: 12
Join SI Premium – FREE
Citi analyst Joel Beatty downgraded PTC Therapeutics (NASDAQ: PTCT) from Buy to Neutral with a price target of $67.00 (from $67.00).
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $53.89 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PTC Therapeutics (PTCT) PT Raised to $130 at Cantor Fitzgerald on PKU Launch
- PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- JPMorgan Downgrades Coles Group Ltd. (COL:AU) (CLEGF) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
